These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 34236497)
1. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. Iacoboni G; Simó M; Villacampa G; Catalá E; Carpio C; Díaz-Lagares C; Vidal-Jordana Á; Bobillo S; Marín-Niebla A; Pérez A; Jiménez M; Abrisqueta P; Bosch F; Barba P Ann Hematol; 2021 Sep; 100(9):2303-2310. PubMed ID: 34236497 [TBL] [Abstract][Full Text] [Related]
2. [ Gui J; Li M; Xu J; Zhang X; Mei H; Lan X Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921 [TBL] [Abstract][Full Text] [Related]
3. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy. Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy. Ladbury C; Hao C; Watkins WT; Sampath S; Wong J; Amini A; Sokolov K; Yeh J; Al Feghali KA; de Jong D; Maniyedath A; Shirvani S; Nikolaenko L; Mei M; Herrera A; Popplewell L; Budde LE; Dandapani S Front Immunol; 2024; 15():1419788. PubMed ID: 39411711 [TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells. Galtier J; Vercellino L; Chartier L; Olivier P; Tabouret-Viaud C; Mesguich C; Di Blasi R; Durand A; Raffy L; Gros FX; Madelaine I; Meignin V; Mebarki M; Rubio MT; Feugier P; Casasnovas O; Meignan M; Thieblemont C Haematologica; 2023 Jan; 108(1):171-180. PubMed ID: 35678029 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305 [TBL] [Abstract][Full Text] [Related]
10. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy. Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707 [TBL] [Abstract][Full Text] [Related]
11. Conventional and novel [ Leithner D; Flynn JR; Devlin SM; Mauguen A; Fei T; Zeng S; Zheng J; Imber BS; Hubbeling H; Mayerhoefer ME; Bedmutha A; Luttwak E; Corona M; Dahi PB; Luna de Abia A; Landego I; Lin RJ; Palomba ML; Scordo M; Park JH; Tomas AA; Salles G; Lafontaine D; Michaud L; Shah GL; Perales MA; Shouval R; Schöder H J Hematol Oncol; 2024 Apr; 17(1):21. PubMed ID: 38649972 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells. Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706 [TBL] [Abstract][Full Text] [Related]
13. Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort. Le Goff E; Blanc-Durand P; Roulin L; Lafont C; Loyaux R; MBoumbae DL; Benmaad I; Claudel A; Poullot E; Robe C; Gricourt G; Aissat A; Copie-Bergman C; Lemonnier F; Gaulard P; Itti E; Haioun C; Delfau-Larue MH Br J Haematol; 2023 Jul; 202(1):54-64. PubMed ID: 37038217 [TBL] [Abstract][Full Text] [Related]
14. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Toledano MN; Desbordes P; Banjar A; Gardin I; Vera P; Ruminy P; Jardin F; Tilly H; Becker S Eur J Nucl Med Mol Imaging; 2018 May; 45(5):680-688. PubMed ID: 29344718 [TBL] [Abstract][Full Text] [Related]
15. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV Zhang YY; Song L; Zhao MX; Hu K Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. Guo B; Tan X; Ke Q; Cen H PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203 [TBL] [Abstract][Full Text] [Related]
18. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT metrics-based stratification of large B-cell lymphoma receiving CAR-T cell therapy: immunosuppressive tumor microenvironment as a negative prognostic indicator in patients with high tumor burden. Sheng LS; Shen R; Yan ZX; Wang C; Zheng X; Zhang YL; Yang HX; Wu W; Xu PP; Cheng S; Bachy E; Sesques P; Jacquet-Francillon N; Jiang XF; Zhao WL; Wang L Biomark Res; 2024 Sep; 12(1):104. PubMed ID: 39272132 [TBL] [Abstract][Full Text] [Related]
20. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]